Key result
Intranasal etripamil cuts ED visits for ongoing PSVT ~39% vs. placebo.
Why the study?
Does self-administered intranasal etripamil reduce emergency department visits in patients experiencing acute episodes of paroxysmal supraventricular tachycardia?
Meta-Analysis (n=340)
Double-blind, placebo-controlled
Randomized
Does self-administered intranasal etripamil reduce emergency department visits in patients experiencing acute episodes of paroxysmal supraventricular tachycardia?
Self-administered intranasal etripamil significantly reduces the need for acute emergency department visits and subsequent medical interventions in patients experiencing paroxysmal supraventricular tachycardia at home.
Answers are grounded in this paper and cite their sources.
Supports at-home etripamil to avert ED visits in PSVT; extends RCT termination data to acute care utilization.
This secondary analysis of a randomized clinical trial describes the use of emergency care after self-administration of etripamil by patients experiencing paroxysmal supraventricular tachycardia episodes at home.
No takes yet. Share an insight, caveat, or question.
Pokorney et al. (2025) conducted a meta-analysis in Paroxysmal Supraventricular Tachycardia (PSVT) (n=340). Etripamil vs. Placebo was evaluated on Emergency department visit for ongoing PSVT within 24 hours of treatment (RR 0.61, 95% CI 0.38-0.97, p=0.04). Self-administered intranasal etripamil reduced the risk of emergency department visits for ongoing PSVT by 39% compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: